Bioventures 2014 L.P. Mpm Sells 26,522 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Key Points

• Major shareholder Bioventures 2014 L.P. Mpm sold 26,522 Entrada Therapeutics shares at an average price of $7.54, worth approximately $199,976. After the sale, it retained 4.33 million shares, representing a 0.61% reduction in ownership.
• Entrada Therapeutics shares fell $0.62 to $7.00, well below the 52-week high of $16.45. The company also missed quarterly earnings and revenue estimates, reporting a loss of $1.01 per share and revenue of $0.90 million.
• Analyst sentiment remains mixed but leans positive, with a consensus “Moderate Buy” rating and an average price target of $17.75; institutional investors own 86.39% of the company.

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) major shareholder Bioventures 2014 L.P. Mpm sold 26,522 shares of the business's stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $7.54, for a total value of $199,975.88. Following the transaction, the insider owned 4,332,917 shares in the company, valued at approximately $32,670,194.18. This represents a 0.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Wednesday, August 26th, Bioventures 2014 L.P. Mpm sold 14,569 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.06, for a total value of $102,857.14.
• On Monday, August 24th, Bioventures 2014 L.P. Mpm sold 21,623 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.34, for a total value of $158,712.82.

Entrada Therapeutics Price Performance

Entrada Therapeutics stock traded down $0.62 during trading on Wednesday, reaching $7.00. 229,319 shares of the company were exchanged, compared to its average volume of 334,500. Entrada Therapeutics, Inc. has a 52-week low of $5.02 and a 52-week high of $16.45. The company has a market capitalization of $272.58 million, a P/E ratio of -1.77 and a beta of -0.26. The stock's 50 day simple moving average is $7.08 and its two-hundred day simple moving average is $9.36.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.04). Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%.The company had revenue of $0.90 million for the quarter, compared to analyst estimates of $2.32 million. As a group, equities analysts forecast that Entrada Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Guggenheim dropped their price objective on shares of Entrada Therapeutics from $20.00 to $17.00 and set a "buy" rating for the company in a report on Monday, June 8th. HC Wainwright downgraded shares of Entrada Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday, May 8th. Weiss Ratings lowered shares of Entrada Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Thursday, August 13th. Finally, Roth Capital reissued a "buy" rating and issued a $11.00 price target on shares of Entrada Therapeutics in a research note on Wednesday, August 12th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $17.75.

Institutional Investors Weigh In On Entrada Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TRDA. State of Wyoming purchased a new position in shares of Entrada Therapeutics during the 2nd quarter worth $37,000. Russell Investments Group Ltd. raised its holdings in Entrada Therapeutics by 72.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company's stock valued at $51,000 after buying an additional 3,707 shares during the period. Occudo Quantitative Strategies LP purchased a new stake in Entrada Therapeutics in the 2nd quarter valued at about $68,000. Jain Global LLC acquired a new position in Entrada Therapeutics in the third quarter valued at about $69,000. Finally, IHT Wealth Management LLC acquired a new position in Entrada Therapeutics in the second quarter valued at about $72,000. Hedge funds and other institutional investors own 86.39% of the company's stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics NASDAQ: TRDA is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source